CTOs on the Move

MAI Medical Aesthetics - Non Surgical Treatments

www.mesoexpert.com

 
MAI Medical Aesthetics - Non Surgical Treatments For Weight Loss in CA is a Roseville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mesoexpert.com
  • 1891 E Roseville Pkwy Ste 170
    Roseville, CA USA 95661
  • Phone: 916.786.6376

Executives

Name Title Contact Details

Similar Companies

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Sinai Residences

Sinai Residences is a retirement community in Boca Raton that offers luxurious surroundings and a culture of sophistication. They provide top-notch independent and assisted living, memory care, rehab, and skilled nursing services on site.

American Board of Family Medicine

American Board of Family Medicine is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PolyNovo Limited

At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.